A groundbreaking gene therapy, VERVE-102, developed by researchers in London, has demonstrated the potential to reduce harmful LDL cholesterol levels by up to 62% with just a single injection. This innovative treatment modifies a gene responsible for cholesterol regulation, offering a promising alternative to daily statin medications that millions rely on.
The therapy’s ability to maintain low cholesterol levels for up to a year could significantly change the landscape of cardiovascular care, particularly for those struggling with adherence to daily medication routines. Many patients abandon statins due to side effects or the challenge of daily compliance, making a one-off treatment highly appealing.
VERVE-102 works by silencing the PCSK9 gene, which normally hinders the body’s ability to clear LDL cholesterol. By effectively mimicking a natural genetic variation that leads to low cholesterol, this therapy could provide a long-term solution for individuals at high risk of cardiovascular diseases.
While the initial trial results are promising, experts urge caution, noting that long-term safety data is still needed. If further trials confirm its efficacy and safety, VERVE-102 could revolutionise cholesterol management and reduce the burden of cardiovascular diseases in the UK and beyond.
Source: GB News
